PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “monkeypox”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources

Clinical, epidemiological, and genomic evidence on mpox in mainland China, 2022-2025: a scoping review.

BACKGROUND: Since 2022, mpox has expanded globally with sustained human-to-human transmission and increasing evidence of MPXV genomic diversification. In mainland China, mpox evidence has accumulated rapidly, but clinical, epidemiological, and genomic findings remain fragmented. METHODS: We conducted a scoping review of PubMed, CNKI, and WanFang databases up to March 2, 2026, and integrated literature-derived evidence with public MPXV sequences from GenBank, GenBase, and GISAID. Literature-derived data were used to map clinical-epidemiological characteristics, study-level genomic evidence, sequencing coverage, and reported lineage distribution. Curated public MPXV sequences were used for phylogenetic reconstruction, amino acid mutation profiling, and APOBEC-like substitution analysis. RESULTS: Fifty-eight studies were included: 32 addressed clinical or epidemiological evidence only, 25 addressed genomic evidence only, and one contributed to both domains. Fourteen hospital-based studies summarized 951 cases, showing that reported cases were concentrated among young adult men, with frequent MSM exposure (798/897, 89.0%; 95% CI 86.7-90.9%) and HIV co-infection (469/951, 49.3%; 95% CI 46.1-52.5%). Public sequence curation identified 231 unique mainland China MPXV sequences, of which 230 were used for phylogenetic and mutation analyses. Literature-based genomic evidence comprised 26 genomic studies, 37 study-level genomic records, and 31 reported-case units, including 414 sequenced cases among 530 reported cases (78.1%; 95% CI 74.4-81.4%). Clade IIb predominated among sequenced cases (412/414, 99.5%; 95% CI 98.3-99.9%), with C.1.1 and C.1 most frequently represented. Within the available dataset, public genomes represented multiple lineages and were unevenly distributed across regions and time. Mutation analysis revealed dispersed amino acid variation and a predominance of G>A and C>T transitions (73.0%). After collapsing recurrent substitutions to unique genomic sites, the proportion of G>A/C>T transitions decreased to 35.8% and further to 17.8% under a strict APOBEC3 motif definition, indicating that the observed mutation spectrum includes both shared lineage-associated substitutions and sequence-context-based APOBEC-like patterns. CONCLUSION: Available evidence indicates multi-lineage MPXV circulation and in mainland China, but interpretation remains constrained by uneven sequencing and lack of individual-level clinical-genomic linkage. Integrated genomic surveillance and standardized data linkage are needed to better characterize MPXV transmission and evolution.

APOBEC‑like substitutions↗

The zoonotic poxviruses.

Animal poxviruses occasionally produce human skin disease often associated with systemic illness. Lesions are painful blisters and crusted eschars and are usually self-limiting and rarely fatal. Treatment is generally supportive.

Diagnosis, Differential↗

Recognizing the real threat of biological terror.

Weapons of mass destruction can be used to harm and terrorize populations. Such weapons include those with chemical, nuclear or biological properties. Obviously computer viruses can add additional barriers to a quick response. The most effective, least costly and greatest threats are biologicals. Biological terror is not new, and biological weapons have been used for centuries. However, as a result of modern technology, the risks are greater now and the outcomes more terrible. Today they include live pathogens, various toxins, and theoretically "bioregulators"--biochemicals affecting cell signaling. Altered cell signaling could be used to induce apoptosis-cell death, or a heightened outpouring of cytokines mimicking overwhelming sepsis, or even an intracellular, biochemical "strike" causing cellular paralysis. Biological weaponeers now have the frightening ability to alter the genetic makeup of pathogens, rendering them resistant not only to available antibiotic therapy but also to currently effective vaccines. In dark corners of some fringe groups, bioweaponeers are searching for the capability of designing pathogens that target specific races, by virtue of discriminating ligands (1). The resulting morbidity and mortality from use of any biological weapons will be accompanied by chaos, governmental and social instability, panic, an extraordinary utilization of available resources, and an ongoing epidemic of sleepless nights (2,3). Herein I will review some of the issues and some of the currently available biological weapons. The major goal is to highlight the clinical presentations of patients with infections that could be used as biological weapons.

Animals↗

Problem pets.

Explore the source record for details and available documents.

Animals↗

[First appearance of monkey pox in human beings in Gabon].

The authors report on the first coming out in Gabon of human monkey-pox. Four children in the same family were simultaneously attacked. In one of the two fatal cases, diagnosis of monkey-pox was confirmed by the isolation of the virus. In the three other cases, diagnosis was based on clinical and epidemiological findings. The coming out of monkey-pox in Gabon squares with sporadic coming out of this zoonosis observed in the humid tropical forests of west and Central Africa. Two fatal cases presented some symptoms of hemorrhagic fever and cutaneous symptoms did not dominate the clinical feature. As a consequence of it, monkey-pox has to be envisaged in similar cases. The attack of liver and spleen in man has not been documented up till now, as it has been for monkeys. Classical diagnosis is based on the isolation of the virus from a cutaneous lesion. In the present case, the virus was isolated from a blood sample. Epidemiological study did not reveal any interhuman transmission evidence, nor the source of infection.

Biopsy↗

Vaccinia (smallpox) vaccine. Recommendations of the Immunization Practices Advisory Committee (ACIP)

These revised recommendations on vaccinia (smallpox) vaccine update the previous recommendations (MMWR 1985; 34:341-2) and include current information on its use among laboratory and health-care workers occupationally exposed to vaccinia, recombinant vaccinia viruses, and other orthopoxviruses that can infect humans. This report also contains revised recommendations on revaccination of high-risk workers and information on contraindications to vaccination.

Centers for Disease Control and Prevention, U.S.↗